CAR-T for blood cancers: understand the available pathways

Clinical availability: Pending confirmation

What this helps you understand

For patients and families exploring CAR-T for selected relapsed or refractory blood cancers. Each product has specific disease and treatment criteria. The first step is to identify whether an approved pathway could be relevant.

Why explore care in China

China has approved CAR-T products and hospitals have reported treating international patients. A meaningful comparison considers the specific indication, clinical team and complete care pathway, rather than the medicine or a single price alone.

Your next step

Contact NEXA to ask about specialist review pathways and current collaboration. A haematology team would need to assess the diagnosis, previous treatment and health status before explaining preparation, cell collection, monitoring and follow-up.

For referring and clinical partners

We welcome qualified CAR-T clinical teams and international referring partners interested in indication review, care during treatment and medical handover after the patient returns home.